Everest Medicines Ltd (FRA:6HN)

Full Year 2024 Everest Medicines Ltd Earnings Call Transcript

Mar 25, 2025 / 01:00 AM GMT

Release Date Price: €6.3 (-13.10%)

Transcript

Key Points

Positve

Everest Medicines Ltd (FRA:6HN) reported a significant 461% year-on-year revenue growth, reaching RMB706.7 million, exceeding their guidance.
The company achieved an impressive gross margin of 83% for the full year 2024, reflecting strong operational efficiency.
Everest Medicines Ltd (FRA:6HN) reduced its net loss by 25% year-on-year, demonstrating improved financial performance.
The company maintains a strong cash balance of RMB1.6 billion, providing flexibility for future growth initiatives.
Everest Medicines Ltd (FRA:6HN) successfully launched new products and expanded its market presence, contributing to revenue growth.

Negative

Despite the revenue growth, Everest Medicines Ltd (FRA:6HN) still reported a net loss of RMB537.6 million for the year.
The company faces evolving competition in the IGA market with multiple drugs entering the market, which could impact future growth.
There is a significant increase in distribution and selling expenses, which rose by RMB276.7 million, reflecting higher costs associated with product launches.
The company has deprioritized its MRNA COVID-19 vaccine program, resulting in a one-time non-recurring intangible asset impairment loss.
Everest Medicines Ltd (FRA:6HN) is still working towards achieving cash flow break-even by the end of 2025, indicating ongoing financial challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

1952.HK - Everest Medicines Ltd
Full Year 2024 Everest Medicines Ltd Earnings Call
Mar 26, 2025 / 01:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning or good evening. Welcome to Everest Medicines full year 2024 financial results conference call.

Please be advised that today's conference is being recorded.

During the PIA session, the participants who join the call through PC or app, please click the raise hand button at the bottom of the screen to queue up for voice questions.

Prote your questions as messages.

For participants who dialed in, please press one to queue up for question.

I would now like to hand a conference over to your speaker today, Miss Lili, please go ahead.

Thank you, operator. Good morning, good evening, everyone. Welcome to our full year 2024 financial results conference call.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.